Publications by authors named "Lawrence Piro"

Claim this Profile
E
Endocrine Autoantibodies Determine Immune Checkpoint Inhibitor-induced Endocrinopathy: A Prospective Study.
Artak Labadzhyan, Kristopher Wentzel, Omid Hamid, Kamlynn Chow, Sungjin Kim, Lawrence Piro

J Clin Endocrinol Metab· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome.
Azra Raza, Naomi Galili, Natalie Callander, Leonel Ochoa, Lawrence Piro

J Hematol Oncol· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma.
Peter D Boasberg, Dave S B Hoon, Lawrence D Piro, Maureen A Martin, Akhide Fujimoto

J Invest Dermatol· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.
Kristie A Blum, Jeffrey L Johnson, Donna Niedzwiecki, Lawrence D Piro, Alan Saven

Cancer· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Khuda D Khan, Christos Emmanouilides, Don M Benson, Deborah Hurst, Pablo Garcia, Lawrence Piro

Clin Cancer Res· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apoptosis, Bcl-2 antisense, and cancer therapy.
Lawrence D Piro

Oncology (Williston Park)· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
Steven J O'Day, Peter D Boasberg, Lawrence Piro, Timothy S Kristedja, He-Jing Wang

Clin Cancer Res· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis